Bristol-Myers Squibb Company (BMY)

56.84
+0.52(+0.92%)
After Hours
56.83
-0.01(-0.02%)
- Real-time Data
  • Volume:
    18,761,032
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    56.59 - 57.54

BMY Overview

Prev. Close
56.32
Day's Range
56.59-57.54
Revenue
45.47B
Open
56.69
52 wk Range
53.22-69.75
EPS
-2.4
Volume
18,761,032
Market Cap
126.16B
Dividend (Yield)
1.96
(3.48%)
Average Vol. (3m)
12,299,708
P/E Ratio
-
Beta
0.58
1-Year Change
-9.61%
Shares Outstanding
2,219,644,935
Next Earnings Date
Feb 04, 2022
What is your sentiment on Bristol-Myers Squibb Company?
or
Market is currently closed. Voting is open during market hours.

Bristol-Myers Squibb Company Company Profile

Employees
30250

Bristol-Myers Squibb Company develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; Inspirna, Inc.; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyNeutralSellSell
Technical IndicatorsNeutralStrong SellStrong BuySellStrong Sell
SummaryNeutralNeutralBuySellStrong Sell
  • Moving on, investors are simply no longer interested in this stock and the executives are not doing anything about it
    0
    • 45
      0
    • There’s just no interest, as the price is already very cheap compared to its value. Perhaps that’s what BMY wants in order to buy back its stock cheap
      0
    • They barely have a few billion each year to buy back stock. Its a bad strategy.
      0
  • welcome to $52 ?
    2
    • Analysis dont care for bmy or phizer and they are the most respectfull and profitable in their area
      0
      • sold half of stock at loss. 57.5 is resistance from here on. Investors are not excited about this as a long term play (due to concerns growth). I'll return here to buy at a later time, when it makes sense to do so. Apparently with this pharma stock it was too soon to invest (as a value play). I'm eating my pride and moving on. Good luck to all.
        3
        • Market is also upset that they do not use cash to make investments.
          0
      • garbage stock
        4
        • Positive or negative news its going down i just dont uderstand
          0
          • Is this the start of a slide-reversal?
            0
            • What's happening?!
              0
              • cheap, so buy, thats what happens
                1
              • Ciprian GalI will when it hits 30
                0
            • Let us hope for negative news on BMY, perhaps we will get an opportunity to buy sub $50. Unlikely but certainly in the realm of possibilities.
              0
              • Establishing strong support at 57, in the making.
                0
                • Stock not going anywhere
                  0
                  • I hope not, this company is a gem. Who wouldn't want to buy a well run company at a great price.
                    0
                • Bmy stock not going any where ❌
                  0
                  • sold puts.
                    0
                    • Not a good company to invest in
                      3
                      • Completely mistaken. BMY has great cash flows (super low P/E when everything else in the market is expensive), a reminder that will come back when earnings report. One thing: this drop presents an oppurtunity to add, done!
                        0
                      • If he's smart he is buying up shares of BMY and hoping he can help supress the market price. At the current price the market assumes no growth for BMY in the near future.
                        0
                    • finally buying more today. Investors forgte that BMY had traded for a time when P/E was 15, while now its PE is half than that. Patience buying, and building position. Lomg term investment.
                      3
                      • Its not going any where
                        0
                    • Why is going down?!
                      0
                      • Everyones top question that no answers are being given. A lot ov good news with the stock, so im just buying at these lows. It’ll be back up
                        0
                    • Forward P/E is 8. Don't be foolded, this is the cheapest on the market (3% yield too). A bit of risk with the White House drug proposals, but no woaries, they will not get passed.
                      3
                      • next leg is melt up....get ready for it. soon.
                        0
                        • Nah not yet. Bmy doesn’t move like that
                          0
                      • buying again today. great deal
                        0
                        • uui
                          1
                          • I have a PT of 102
                            0
                            • long term buy at this level. support at around 67 established strongly
                              0
                              • after the fed today, time to buy some more.
                                0
                                • looks like we're hittin support at 67. Forward P/E looks in line with a move up. Revlimid,Eliquis, Opdivo (Myeloma, NOAC, Oncology) all leaders. No advice
                                  0
                                  • when 10 y yields go down, this is the stock to buy
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.